These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22899473)

  • 1. CCR1 blockade and myeloma bone disease.
    Sebag M
    Blood; 2012 Aug; 120(7):1351-2. PubMed ID: 22899473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
    Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
    Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR1 as a target for multiple myeloma.
    Vallet S; Anderson KC
    Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
    Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
    Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of CCR1 antagonists for multiple myeloma.
    Karash AR; Gilchrist A
    Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
    Gilchrist A; Echeverria SL
    Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
    Vallet S; Raje N; Ishitsuka K; Hideshima T; Podar K; Chhetri S; Pozzi S; Breitkreutz I; Kiziltepe T; Yasui H; Ocio EM; Shiraishi N; Jin J; Okawa Y; Ikeda H; Mukherjee S; Vaghela N; Cirstea D; Ladetto M; Boccadoro M; Anderson KC
    Blood; 2007 Nov; 110(10):3744-52. PubMed ID: 17715391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights in myeloma-induced osteolysis.
    Barillé-Nion S; Bataille R
    Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.
    Chou CC; Fine JS; Pugliese-Sivo C; Gonsiorek W; Davies L; Deno G; Petro M; Schwarz M; Zavodny PJ; Hipkin RW
    Br J Pharmacol; 2002 Nov; 137(5):663-75. PubMed ID: 12381680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential chemokine activation of CC chemokine receptor 1-regulated pathways: ligand selective activation of Galpha 14-coupled pathways.
    Tian Y; New DC; Yung LY; Allen RA; Slocombe PM; Twomey BM; Lee MMK; Wong YH
    Eur J Immunol; 2004 Mar; 34(3):785-795. PubMed ID: 14991608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice.
    Repeke CE; Ferreira SB; Claudino M; Silveira EM; de Assis GF; Avila-Campos MJ; Silva JS; Garlet GP
    Bone; 2010 Apr; 46(4):1122-30. PubMed ID: 20053385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells.
    Pevida M; Lastra A; Meana Á; Hidalgo A; Baamonde A; Menéndez L
    Neuroscience; 2014 Feb; 259():113-25. PubMed ID: 24316469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4.
    Ramos CD; Canetti C; Souto JT; Silva JS; Hogaboam CM; Ferreira SH; Cunha FQ
    J Leukoc Biol; 2005 Jul; 78(1):167-77. PubMed ID: 15831559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporal CCR1, CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain.
    Knerlich-Lukoschus F; von der Ropp-Brenner B; Lucius R; Mehdorn HM; Held-Feindt J
    J Neurosurg Spine; 2011 May; 14(5):583-97. PubMed ID: 21332278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.